Antigen-specific targeting of immune system offers treatment approach to improve efficacy of biologic drugs

August 1, 2016, Selecta Biosciences

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company developing targeted antigen-specific immune therapies for rare and serious diseases, announced today that Nature Nanotechnology has published an article that presents preclinical results from Selecta's research which demonstrate the broad potential applicability of Selecta's novel immune tolerance platform. Details that elucidate the mechanism of action of the company's immune tolerance therapy, SVP-Rapamycin (SEL-110), were also shown. Data in the publication support the Company's lead clinical program, showing Selecta's SVP-Rapamycin (SEL-110) induces antigen-specific immune tolerance and mitigates the formation of anti-drug antibodies (ADAs) to biologic drugs, including pegsiticase (for gout) and adalimumab (for rheumatoid arthritis).

"Undesired immune responses affect both the efficacy and safety of marketed biologic therapies and the development of otherwise promising new technologies. Selecta's SVP platform positions the company to enhance biologic therapy and to advance a pipeline of proprietary products that meet the therapeutic needs of patients with rare and serious diseases," said Werner Cautreels, PhD,Chairman of the Board, CEO and President of Selecta Biosciences. "This publication in Nature Nanotechnology highlights the mechanism by which Selecta's proprietary nanoparticles induce lasting antigen-specific tolerance. We believe that SVP-Rapamycin has the potential to mitigate ADAs against a broad range of biologic therapies."

In the Nature Nanotechnology journal article, Selecta presents validation of the immune tolerance mechanism of action of the company's technology, demonstrating that poly(lactic-co-glycolic acid) (PLGA) nanoparticles encapsulating rapamycin, but not free rapamycin, are capable of inducing durable immunological tolerance to co-administered proteins. This robust immune tolerance is characterized immunologically by: (1) induction of tolerogenic dendritic cells; (2) an increase in regulatory T cells; (3) reduction in B cell activation and germinal center formation; and (4) inhibition of antigen-specific hypersensitivity reactions.

Data presented in the journal article support the Company's clinical lead program in gout, showing that intravenous co-administration of tolerogenic nanoparticles with pegylated uricase inhibited the formation of ADAs in mice and nonhuman primates and normalized serum uric acid levels in uricase-deficient mice. Underscoring the broad potential of the approach, results additionally show that subcutaneous co-administration of nanoparticles with adalimumab durably inhibited ADAs, resulting in normalized pharmacokinetics of the anti-TNFα antibody and protection against arthritis in TNFα transgenic mice.

In the published research, the induction of specific immune tolerance by SVP-Rapamycin (SEL-110) versus chronic immune suppression is supported by the findings that: (1) antigen must be co-administered at the time of SVP-Rapamycin (SEL-110) treatment; (2) is durable to many challenges of antigen alone; (3) animals tolerized to a specific antigen are capable of responding to an unrelated antigen, meaning that SVP-Rapamycin (SEL-110) does not induce a broad immune suppression; and (4) activation of naïve T cells is inhibited when adoptively transferred into previously tolerized mice. In contrast, daily administration of free rapamycin, at five times the total weekly rapamycin dose as that administered in the SVP-Rapamycin, was observed to transiently suppress the immune response, but did not induce durable immunological tolerance.

Explore further: Parasite proteins prompt immune system to fight off ovarian tumors in mice

More information: Improving the Efficacy and Safety of Biologic Drugs with Tolerogenic Nanoparticles, Nature Nanotechnology, nature.com/articles/doi:10.1038/nnano.2016.135

Related Stories

Transplant drug may provide benefits after spinal cord injury

July 8, 2016

New research in mice indicates that a drug commonly used to suppress the immune system in recipients of organ transplants may also reduce tissue damage and neuropathic pain after spinal cord injury. The findings are published ...

Nicotine vaccine prevents nicotine from reaching the brain

May 2, 2012

If smoking a cigarette no longer delivers pleasure, will smokers quit? It's the idea behind a nicotine vaccine being created by MIT and Harvard researchers, in which an injection of synthetic nanoparticles prompts the immune ...

Recommended for you

Solution for next generation nanochips comes out of thin air

November 19, 2018

Researchers at RMIT University have engineered a new type of transistor, the building block for all electronics. Instead of sending electrical currents through silicon, these transistors send electrons through narrow air ...

Scientists create atomic scale, 2-D electronic kagome lattice

November 19, 2018

Scientists from the University of Wollongong (UOW), working with colleagues at China's Beihang University, Nankai University, and Institute of Physics at Chinese Academy of Sciences, have successfully created an atomic scale, ...

Graphene flickers at 400Hz in 2500ppi displays

November 16, 2018

With virtual reality (VR) sizzling in every electronic fair, there is a need for displays with higher resolution, frame rates and power efficiency. Now, a joint collaboration of researchers from SCALE Nanotech, Graphenea ...

Solving mazes with single-molecule DNA navigators

November 16, 2018

The field of intelligent nanorobotics is based on the great promise of molecular devices with information processing capabilities. In a new study that supports the trend of DNA-based information carriers, scientists have ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.